Open AccessThe impact of immune checkpoint therapy on the latent reservoir in HIV infected individuals with cancer on antiretroviral therapy
Author(s) -
Jillian S.Y. Lau,
James McMahon,
Céline Gubser,
Ajantha Solomon,
Chris Chiu,
Ashanti Dantanarayana,
Socheata Chea,
Surekha Tennakoon,
Jennifer M. Zerbato,
Jill S. Garlick,
Vincent Morcilla,
Sarah Palmer,
Sharon R Lewin,
Thomas A. Rasmussen
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002919
Subject(s) - nivolumab , ipilimumab , immunology , medicine , avelumab , cd8 , merkel cell carcinoma , immune checkpoint , immune system , virology , oncology , immunotherapy , carcinoma
The aim of this study was to quantify HIV-specific immunological and virological changes in people with HIV (PWH) on antiretroviral therapy (ART) with malignancy who received immune checkpoint blockade (ICB).